[
    [
        {
            "time": "2018-01-02",
            "original_text": "汇安基金一哥戴杰光环迅速消退，重仓核心资产退步明显",
            "features": {
                "keywords": [
                    "汇安基金",
                    "戴杰光",
                    "重仓核心资产",
                    "退步"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "汇安基金一哥戴杰光环迅速消退，重仓核心资产退步明显",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-30",
            "original_text": "【招商策略】股市流动性改善，科创板纳入沪港通指日可待 —— 金融市场流动性与监管动态周报（1130）",
            "features": {
                "keywords": [
                    "招商策略",
                    "股市流动性",
                    "科创板",
                    "沪港通"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【招商策略】股市流动性改善，科创板纳入沪港通指日可待 —— 金融市场流动性与监管动态周报（1130）",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "陆股通净买入49.39亿元，连续3日净买入",
            "features": {
                "keywords": [
                    "陆股通",
                    "净买入",
                    "连续3日"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "陆股通净买入49.39亿元，连续3日净买入",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-28",
            "original_text": "67个新药获批临床：恒瑞、先声、石四药",
            "features": {
                "keywords": [
                    "新药",
                    "恒瑞",
                    "先声",
                    "石四药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "67个新药获批临床：恒瑞、先声、石四药",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-27",
            "original_text": "医药行业每周医览药闻：全国高耗集采 —— 加速进口替代，推进产业创新",
            "features": {
                "keywords": [
                    "医药行业",
                    "高耗集采",
                    "进口替代",
                    "产业创新"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业每周医览药闻：全国高耗集采 —— 加速进口替代，推进产业创新",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-26",
            "original_text": "信达生物（01801.HK）：达伯舒+达莜同肝癌疗效良好，看好中期前景，维持“买入”评级，目标价69.4 港元",
            "features": {
                "keywords": [
                    "信达生物",
                    "达伯舒",
                    "达莜同",
                    "肝癌",
                    "买入评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "信达生物（01801.HK）：达伯舒+达莜同肝癌疗效良好，看好中期前景，维持“买入”评级，目标价69.4 港元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-25",
            "original_text": "北向资金一周动向盘点：净买168.5亿元，盯住新能源、非银",
            "features": {
                "keywords": [
                    "北向资金",
                    "新能源",
                    "非银",
                    "净买"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "新能源",
                    "非银"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北向资金一周动向盘点：净买168.5亿元，盯住新能源、非银",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]